CJC-1295 DAC (5mg)

Research Overview, Peptide Science and Key Facts

CJC-1295 DAC (5mg) is an investigational peptide that has attracted considerable interest within peptide research, endocrinology, biotechnology, and growth hormone-related research. The compound is a modified growth hormone-releasing hormone, or GHRH, analogue designed to have a substantially longer duration of activity than native GHRH.

The “DAC” designation refers to the Drug Affinity Complex, a structural modification designed to increase the peptide’s association with serum proteins and extend its circulation time. This makes CJC-1295 DAC particularly interesting to researchers studying sustained GHRH receptor signalling and growth hormone physiology.

For researchers interested in peptide science, understanding the structure, mechanism, research history, and limitations of CJC-1295 DAC (5mg) provides valuable insight into this experimental compound.

What Is CJC-1295 DAC?

CJC-1295 DAC is a synthetic analogue of growth hormone-releasing hormone. GHRH is a naturally occurring hormone involved in regulating the release of growth hormone from the pituitary gland.

CJC-1295 was developed with modifications intended to increase its stability and duration of action. The DAC modification is particularly important because it allows the peptide to bind to circulating albumin and other serum proteins, helping reduce rapid clearance.

Human research has demonstrated that CJC-1295 can produce a sustained increase in growth hormone and IGF-1 concentrations after administration.

What Does CJC-1295 DAC (5mg) Mean?

The term CJC-1295 DAC (5mg) refers to a research product containing a stated quantity of 5 milligrams of CJC-1295 with the Drug Affinity Complex modification.

The 5mg specification describes the amount of research material supplied. It should not be interpreted as a recommended human dosage or treatment protocol.

Researchers evaluating peptide materials should consider product identity, purity, batch information, analytical testing, storage requirements, and available documentation.

How Does CJC-1295 DAC Work?

CJC-1295 DAC is designed to interact with the growth hormone-releasing hormone receptor.

GHRH normally binds to receptors on pituitary somatotroph cells, stimulating the release of growth hormone. CJC-1295 was designed to mimic aspects of GHRH activity while remaining in circulation for substantially longer.

The DAC modification contributes to this extended activity by increasing binding to serum proteins.

This makes CJC-1295 DAC scientifically different from short-acting GHRH analogues and allows researchers to investigate more sustained stimulation of the GHRH pathway.

CJC-1295 DAC and Growth Hormone Research

Growth hormone is involved in a wide range of physiological processes, including growth, metabolism, and regulation of IGF-1.

Researchers have studied CJC-1295 DAC to better understand how prolonged GHRH receptor stimulation influences the growth hormone axis.

In a published human study, CJC-1295 administration produced substantial and sustained increases in growth hormone and IGF-1 concentrations. The researchers reported that the compound had a half-life of several days, illustrating the prolonged pharmacological activity created by the DAC modification.

These findings make CJC-1295 DAC an important research tool for investigating endocrine signalling.

CJC-1295 DAC vs. CJC-1295 Without DAC

The distinction between DAC and non-DAC versions is important.

The DAC modification was developed to extend the compound’s circulation time. Without this modification, GHRH analogues generally have substantially shorter activity.

As a result, researchers investigating CJC-1295 should pay attention to the exact compound being studied. CJC-1295 DAC and shorter-acting GHRH analogues should not automatically be treated as interchangeable research materials.

Why Are Researchers Interested in CJC-1295 DAC?

CJC-1295 DAC is interesting because it provides researchers with a model for studying prolonged GHRH signalling.

Research applications can include investigation of:

• Growth hormone regulation
• GHRH receptor signalling
• IGF-1 physiology
• Endocrine pathways
• Peptide pharmacokinetics
• Protein binding
• Long-acting peptide design
• Structure-activity relationships

The compound is also an example of how peptide engineering can change the pharmacokinetic properties of a naturally inspired molecule.

CJC-1295 DAC and IGF-1 Research

IGF-1, or insulin-like growth factor 1, is an important downstream component of the growth hormone axis.

When growth hormone increases, IGF-1 production can also increase. Researchers therefore monitor IGF-1 when investigating compounds that influence GHRH and growth hormone signalling.

Human studies of CJC-1295 have reported sustained increases in IGF-1 following administration.

However, an increase in a biological marker should not automatically be interpreted as evidence that an investigational peptide provides a particular health, fitness, anti-ageing, or performance benefit.

Product Quality and Research Considerations

When evaluating CJC-1295 DAC (5mg) for legitimate research, product characterisation is an important consideration.

Researchers may want to review:

• Peptide identity
• Stated quantity
• Purity information
• Lot or batch number
• Certificate of Analysis, where available
• Analytical testing
• Storage requirements
• Manufacturer or supplier information

Peptide purity and stability can influence experimental reproducibility. Proper documentation is therefore valuable when comparing research materials or designing laboratory experiments.

Is CJC-1295 DAC FDA Approved?

CJC-1295 DAC should not be represented as an FDA-approved treatment for growth hormone deficiency, weight management, muscle development, anti-ageing, or another medical condition.

The FDA has also identified CJC-1295 among bulk drug substances for which safety concerns are relevant in the context of compounding, including limited safety information and concerns surrounding impurities and peptide characterisation.

Researchers and businesses should therefore distinguish carefully between experimental peptide research and approved pharmaceutical therapies.

Frequently Asked Questions About CJC-1295 DAC (5mg)

What is CJC-1295 DAC?

CJC-1295 DAC is an experimental analogue of growth hormone-releasing hormone designed to provide prolonged activity through the Drug Affinity Complex modification.

What does CJC-1295 DAC 5mg mean?

The 5mg designation refers to the stated quantity of CJC-1295 DAC contained in the research product. It does not represent a recommended therapeutic dosage.

What does DAC mean in CJC-1295 DAC?

DAC stands for Drug Affinity Complex. It refers to a modification designed to increase the peptide’s association with serum proteins and extend its circulation time.

What does CJC-1295 research focus on?

Research has investigated CJC-1295 in relation to GHRH receptor signalling, growth hormone secretion, IGF-1 levels, and peptide pharmacokinetics.

Does CJC-1295 DAC increase growth hormone?

Human research has demonstrated that CJC-1295 can produce sustained increases in growth hormone and IGF-1. However, research findings should not be interpreted as a recommendation for human use.

Is CJC-1295 DAC the same as growth hormone?

No. CJC-1295 DAC is a synthetic GHRH analogue. It is not human growth hormone.

Is CJC-1295 DAC FDA-approved?

No. It should not be marketed as an FDA-approved treatment for growth hormone deficiency or other medical conditions.

Why is CJC-1295 DAC interesting to peptide researchers?

Its extended pharmacokinetic profile makes it useful for investigating prolonged GHRH receptor stimulation and the relationship between GHRH, growth hormone, and IGF-1.

How should researchers evaluate CJC-1295 DAC products?

Researchers should examine identity, purity, quantity, analytical documentation, batch information, storage requirements, and applicable laboratory standards.

Final Thoughts on CJC-1295 DAC (5mg)

CJC-1295 DAC (5mg) represents an interesting development in long-acting peptide research. By combining a GHRH analogue with the Drug Affinity Complex modification, researchers can investigate prolonged stimulation of the growth hormone signalling pathway.

Human research has provided evidence that CJC-1295 can substantially and persistently influence growth hormone and IGF-1 concentrations, making the compound particularly relevant to studies of endocrine physiology and peptide pharmacokinetics.

At the same time, it is important to distinguish scientific research from approved medical applications. CJC-1295 DAC should not be promoted as a proven treatment, performance enhancer, or anti-ageing therapy.

For researchers and biotechnology professionals, examining the peptide’s structure, pharmacology, analytical characterisation, and regulatory status provides a responsible foundation for understanding CJC-1295 DAC (5mg).

Research Use Notice: CJC-1295 DAC is an investigational peptide. This information is provided for educational and scientific purposes only and does not constitute medical advice, treatment recommendations, or instructions for human use.